Skip to main content

Table 3 Different treatment for each group of mice

From: pH-sensitive nanoformulation of acetyl-11-keto-beta-boswellic acid (AKBA) as a potential antiproliferative agent in colon adenocarcinoma (in vitro and in vivo)

Groups

 

Treatment condition

1

Healthy control

Weekly IP normal saline for 15 weeks/Normal saline gavage weekly for weeks 16–23

2

Placebo

DMH** (20 mg/Kg, I.P.) weekly for 15 weeks/Normal Saline Gavage Placebo for weeks 16–23

3

Nanocarrier

DMH (20 mg/Kg, I.P.) weekly for 15 weeks/Blank Nanocarrier for weeks 16–23

4

5-FU

DMH (20 mg/Kg, I.P.) weekly for 15 weeks/25 mg/Kg 5-FU for weeks 16–23

5

BA-Ex

DMH (20 mg/Kg, I.P.) weekly for 15 weeks/100 mg/Kg BA-Ex for weeks 16–23

6

Nano-BA-Ex

DMH (20 mg/Kg, I.P.) weekly for 15 weeks/100 mg/Kg Nano-BA-Ex for weeks 16 to 23

7

Nano-BA-Ex/5-FU

DMH (20 mg/Kg, I.P.) weekly for 15 weeks/100 mg/Kg Nano-BA-Ex + 25 mg/Kg 5-FU for weeks 16–23

  1. * N,N′-Dimethylhydrazine dihydrochloride